About Us

Our Value Proposition

For Patients & Healthcare Professionals

By accelerating high unmet needs programs into Japan, we impact the 'access to medicines' problem

For Global Innovators

We deliver access to Japan's $120B market, increasing revenue opportunities and typically adding 10% or more to corporate valuation

For Longevity Enthusiasts

We open the door to world-leading healthy longevity, including cell therapies unavailable elsewhere

HekaBio is a platform for in-licensing, development and commercialization of world-leading biopharma and MedTech assets in Japan and the APAC region.

We recently secured the first ever Japan approval of a foreign-originated new medical device before the US or Europe. We are starting commercial sales in Q4 2026.

We have business licenses and certifications in 4 areas--medical devices, pharmaceuticals, regenerative medicine products and in-vitro diagnostics.

Beyond development and commercialization of our own portfolio, we are able to offer BD & licensing support, clinical and regulatory development and designated marketing authorization holder (DMAH) services for companies wishing to access and build value in Japan.

Why HekaBio?

Deep expertise in Japan and Asia Pacific healthcare markets
Experience across pharmaceuticals, medical devices, diagnostics, and regenerative medicine
Strong network of regulatory, clinical, and commercial stakeholders
Proven track record in product development, regulatory strategy, and market entry
Practical, partnership-driven approach to commercialization

Our Mission

Accelerating patient access to world-leading healthcare solutions

throughout the APAC region, starting with Japan

Our Core Values

Meaning of "Heka"

Egyptian god of

Magic and Medicine